ARID4B and gastric cancer: We successfully prepared a novel anti-BRCAA1-FMNPs nanoprobes, which can be used for in vivo two modal imaging such as fluorescent imaging and magnetic resonance imaging, and own an obviously specific targeting ability toward a gastric cancer tissues with 5 mm in diameter during 0.5 h and 12 h of post-injection, and own good biocompatibility.